Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J V Teichmann

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Die Rehabilitation|February 7, 2002
[Oncological rehabilitation: evaluation of the efficiency of inpatient rehabilitation]J V Teichmann
Leukemia Research|January 1, 1992
Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factorJ V Teichmann, W D Ludwig, E Thiel
Natural Immunity|May 1, 1992
Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samplesJ V Teichmann, W D Ludwig, E Thiel
Leukemia & Lymphoma|July 29, 2016
Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in VivoJ V Teichmann, W D Ludwig, E Thiel
International Journal of Hematology|June 1, 1992
GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cellsJ V Teichmann, W D Ludwig, E Thiel
Immunobiology|December 1, 1988
Abnormalities of B cell activation and immunoregulation in patients with chronic inflammatory liver diseasesG Sieber, J V Teichmann, B Möller, et al.
Cancer|May 15, 1989
Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patientsJ V Teichmann, G Sieber, W D Ludwig, et al.
Journal of Interferon Research|February 1, 1988
Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemiaJ V Teichmann, G Sieber, W D Ludwig, et al.
Blut|July 1, 1989
Induction of lymphokine-activated killer cell against human leukemia cells in vitroJ V Teichmann, W D Ludwig, H Seibt-Jung, et al.
Leukemia Research|January 1, 1986
Chronic myelocytic leukemia as a second neoplasia in the course of chronic lymphocytic leukemia. Case report and review of the literatureJ V Teichmann, G Sieber, W D Ludwig, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Die Rehabilitation|February 7, 2002
[Oncological rehabilitation: evaluation of the efficiency of inpatient rehabilitation]J V Teichmann
Leukemia Research|January 1, 1992
Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factorJ V Teichmann, W D Ludwig, E Thiel
Natural Immunity|May 1, 1992
Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samplesJ V Teichmann, W D Ludwig, E Thiel
Leukemia & Lymphoma|July 29, 2016
Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in VivoJ V Teichmann, W D Ludwig, E Thiel
International Journal of Hematology|June 1, 1992
GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cellsJ V Teichmann, W D Ludwig, E Thiel
Immunobiology|December 1, 1988
Abnormalities of B cell activation and immunoregulation in patients with chronic inflammatory liver diseasesG Sieber, J V Teichmann, B Möller, et al.
Cancer|May 15, 1989
Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patientsJ V Teichmann, G Sieber, W D Ludwig, et al.
Journal of Interferon Research|February 1, 1988
Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemiaJ V Teichmann, G Sieber, W D Ludwig, et al.
Blut|July 1, 1989
Induction of lymphokine-activated killer cell against human leukemia cells in vitroJ V Teichmann, W D Ludwig, H Seibt-Jung, et al.
Leukemia Research|January 1, 1986
Chronic myelocytic leukemia as a second neoplasia in the course of chronic lymphocytic leukemia. Case report and review of the literatureJ V Teichmann, G Sieber, W D Ludwig, et al.
Pageof 2